Compare NNI & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNI | CRSP |
|---|---|---|
| Founded | 1978 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.9B |
| IPO Year | 2003 | 2016 |
| Metric | NNI | CRSP |
|---|---|---|
| Price | $140.78 | $50.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 17 |
| Target Price | ★ $140.00 | $70.29 |
| AVG Volume (30 Days) | 131.4K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | ★ 134.86 | N/A |
| EPS | ★ 11.79 | N/A |
| Revenue | N/A | ★ $289,590,000.00 |
| Revenue This Year | $2.28 | $807.72 |
| Revenue Next Year | $5.38 | $172.52 |
| P/E Ratio | $11.94 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $104.50 | $33.03 |
| 52 Week High | $142.87 | $78.48 |
| Indicator | NNI | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 70.77 | 42.26 |
| Support Level | $128.24 | $44.82 |
| Resistance Level | $141.87 | $60.45 |
| Average True Range (ATR) | 3.05 | 2.75 |
| MACD | 0.83 | -0.02 |
| Stochastic Oscillator | 95.59 | 14.32 |
Nelnet Inc is a United States based company engaged in these four reportable segments; Loan Servicing and Systems focuses on student and consumer loan origination services and servicing, loan origination and servicing-related technology solutions, and outsourcing business services; Education Technology Services and Payments segment provides education services, payment technology, and community management solutions for K-12 schools, institutions, churches, and businesses; Asset Generation and Management segment includes the acquisition and management of student and other loan assets; and Nelnet Bank focuses on the private education and unsecured consumer loan markets. Maximum revenue for the company is generated from its Education Technology Services and Payments segment.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.